UY32752A - Polipéptidos y Métodos de Tratamiento - Google Patents

Polipéptidos y Métodos de Tratamiento

Info

Publication number
UY32752A
UY32752A UY0001032752A UY32752A UY32752A UY 32752 A UY32752 A UY 32752A UY 0001032752 A UY0001032752 A UY 0001032752A UY 32752 A UY32752 A UY 32752A UY 32752 A UY32752 A UY 32752A
Authority
UY
Uruguay
Prior art keywords
treatment methods
polypeptides
antigen binding
binding proteins
pharmaceutical compositions
Prior art date
Application number
UY0001032752A
Other languages
English (en)
Inventor
Michael Neil Burden
Paul Andrew Hamblin
Jonathan David Larkin
John Richard White
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY32752A publication Critical patent/UY32752A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se proporciona en la presente memoria una proteína de unión a antígeno aislado que comprende al menos un primer dominio variable de inmunoglobulina capaz de unirse a la ADAMTS5 humana. También se proporcionan proteínas de unión a antígeno de la presente invención que son anticuerpos monoclonales, composiciones farmacéuticas que comprenden dichas proteínas de unión a antigeno y métodos de tratamiento.
UY0001032752A 2009-07-02 2010-07-01 Polipéptidos y Métodos de Tratamiento UY32752A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22252109P 2009-07-02 2009-07-02
US24975709P 2009-10-08 2009-10-08

Publications (1)

Publication Number Publication Date
UY32752A true UY32752A (es) 2011-01-31

Family

ID=43411744

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032752A UY32752A (es) 2009-07-02 2010-07-01 Polipéptidos y Métodos de Tratamiento

Country Status (21)

Country Link
US (1) US20120095193A1 (es)
EP (1) EP2449127A4 (es)
JP (1) JP2012531902A (es)
KR (1) KR20120098587A (es)
CN (1) CN102482700A (es)
AR (1) AR077630A1 (es)
AU (1) AU2010266272A1 (es)
BR (1) BR112012000025A2 (es)
CA (1) CA2766641A1 (es)
CL (1) CL2011003354A1 (es)
CO (1) CO6480976A2 (es)
CR (1) CR20120027A (es)
DO (1) DOP2011000404A (es)
IL (1) IL217292A0 (es)
MA (1) MA33387B1 (es)
MX (1) MX2012000055A (es)
PE (1) PE20120554A1 (es)
SG (1) SG177288A1 (es)
TW (1) TW201114436A (es)
UY (1) UY32752A (es)
WO (1) WO2011002968A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
EP2678027A4 (en) * 2011-02-24 2015-09-02 Glaxo Group Ltd METHODS OF IDENTIFYING PATIENT POPULATION
WO2013109829A1 (en) * 2012-01-20 2013-07-25 Glaxosmithkline Intellectual Property Development Ltd Anti-adamts4 antibodies and methods of treatment
EP2650310B1 (en) 2012-04-13 2016-06-08 Rottapharm Biotech S.r.l. Anti-ADAMTS-5 antibody, derivatives and uses thereof
WO2015056808A1 (en) * 2013-10-15 2015-04-23 Genefrontier Corporation Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
WO2017019729A1 (en) * 2015-07-27 2017-02-02 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
TWI826376B (zh) 2017-06-02 2023-12-21 德商麥克專利有限公司 與ａｄａｍｔｓ５、ｍｍｐ１３及聚集蛋白聚醣結合的多肽
EP3630847A1 (en) 2017-06-02 2020-04-08 Merck Patent GmbH Adamts binding immunoglobulins
US20200190216A1 (en) * 2017-06-02 2020-06-18 Merck Patent Gmbh Mmp13 binding immunoglobulins
JPWO2019093497A1 (ja) * 2017-11-09 2021-01-21 株式会社リボミック Ａｄａｍｔｓ５に対するアプタマー及びその使用
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
CN115052897A (zh) * 2020-01-28 2022-09-13 普洛迈博生物技术公司 PLAP-CD3ε双特异性抗体
WO2024054922A1 (en) * 2022-09-07 2024-03-14 Synoa Therapeutics, Llc Methods and compositions comprising novel bispecific antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
JP2007525406A (ja) * 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法

Also Published As

Publication number Publication date
US20120095193A1 (en) 2012-04-19
JP2012531902A (ja) 2012-12-13
CN102482700A (zh) 2012-05-30
AR077630A1 (es) 2011-09-14
TW201114436A (en) 2011-05-01
KR20120098587A (ko) 2012-09-05
IL217292A0 (en) 2012-02-29
PE20120554A1 (es) 2012-06-08
MX2012000055A (es) 2012-01-27
AU2010266272A1 (en) 2012-01-19
CL2011003354A1 (es) 2012-07-20
BR112012000025A2 (pt) 2015-09-08
MA33387B1 (fr) 2012-06-01
SG177288A1 (en) 2012-02-28
DOP2011000404A (es) 2012-04-15
CA2766641A1 (en) 2011-01-06
CR20120027A (es) 2012-05-16
WO2011002968A3 (en) 2011-04-07
EP2449127A2 (en) 2012-05-09
EP2449127A4 (en) 2013-01-16
CO6480976A2 (es) 2012-07-16
WO2011002968A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
UY32752A (es) Polipéptidos y Métodos de Tratamiento
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
AR121002A2 (es) Método de detección y aislamiento de células productoras de altos niveles de una proteína heterodimérica
EA201892793A1 (ru) Анти-hla-g специфические антитела
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
DOP2013000129A (es) PROTEÍNAS DE UNIÓN AL TNF-a.
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
MX2018009228A (es) Proteínas de unión a antigeno que se unen a pd-l1.
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
ECSP12012272A (es) Proteínas que se unen al tnf-?
CR20140585A (es) Proteinas de union a antigeno st2
IN2014MN00873A (es)
EA201490677A1 (ru) Связывающие антиген cd27l белки
CR11030A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpos y fragmentos de anticuerpos, que se unen especificamente a cd154 y sus usos
NZ701444A (en) Antibodies to matrix metalloproteinase 9
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
ECSP11011445A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b
BRPI1014544B8 (pt) anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
EA201890928A1 (ru) Антигенсвязывающие белки, которые активируют лептиновый рецептор
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
NZ594682A (en) Fully human antibodies specific to cadm1
MD3365367T2 (ro) Anticorpi monoclonali împotriva ploşniţelor de pat și procedee de obţinere și utilizare a acestora